NS2359 is a mixed monoamine reuptake inhibitor. A study looked at the efficacy of NS2359 versus placebo in a double-blind randomized trial.
There was no statistical difference in the total ADHD-RS scale score between those taking NS2359 and placebo. However, when looking at the inattentive type of ADHD, 41% of those who took NS2359 had an improvement, compared with 7% of the control group.
Wilens, et al. (2008). A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD. Behavioral and Brain Functions 4(24).
http://www.behavioralandbrainfunctions.com/content/4/1/24
Tags: ADD, ADHD, ADHD-RS, clinical trial, Medication, NS2359, placebo, study
This entry was posted by admin on Wednesday, June 25th, 2008 at 11:42 pm and is filed under
ADHD, Medication, Research. You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, or trackback from your own site.
